ReviewNature reviews. Immunology2024
The immunopathogenesis of narcolepsy type 1.
Review in Nature reviews. Immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Narcolepsy: a machine learning bibliometric analysis (1996-2024).Frontiers in neurology · 2025Pooled it
- Narcolepsy is (not) an autoimmune disease.Nature reviews. Neurology · 2026Review
- Non-canonical clonal expansion of autoreactive CD8Cell insight · 2026Article
- Immunocyte phenotypes underlying the causal autoimmune features in narcolepsy type 1.Journal of thoracic disease · 2026Article
- Article
- Protein Acylation Modifications in Sleep Disorders: Mechanisms and Therapeutic Potential.Journal of molecular neuroscience : MN · 2026Review
- Narcolepsy: immunity, neural circuitry, and brain network reconfiguration.Frontiers in immunology · 2026Review
- Bioinformatics identification and experimental validation of hub genes associated with narcolepsy type 1.Journal of clinical and translational science · 2026Article
- Cytokines in narcolepsy type 1: pathogenic relevance, biomarker potential, and future directions.Frontiers in neurology · 2026Review
- Medication Treatment Modulates Sleep Architecture and Cognitive-Related Cortical Hemodynamics in Narcolepsy Type 1.Nature and science of sleep · 2026Article
- Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine.Frontiers in psychiatry · 2026Review
- Narcolepsy Associated With Streptococcal Infection: A Case Report and Literature Review.Clinical case reports · 2025Article
- A Comprehensive Review of Current and Emerging Treatments for Narcolepsy Type 1.Journal of clinical medicine · 2025Review
- Present and Future of Central Disorders of Hypersomnolence.Journal of sleep research · 2025Review
- Integrative sleep management: from molecular pathways to conventional and herbal treatments.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Sleep Disruption and Atrial Fibrillation: Evidence, Mechanisms and Clinical Implications.Circulation research · 2025Review
- Global estimates of vaccine-associated narcolepsy from 1967 to 2023.Scientific reports · 2025Article
- Narcolepsy and rapid eye movement sleep.Journal of sleep research · 2025Review
- Ofatumumab treatment in new-onset narcolepsy type 1 following SARS-CoV-2 infection.Annals of clinical and translational neurology · 2025Article
- Human genetics of responses to vaccines.Clinical and experimental immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Narcolepsy type 1 (NT1) is a chronic sleep disorder resulting from the loss of a small population of hypothalamic neurons that produce wake-promoting hypocretin (HCRT; also known as orexin) peptides. An immune-mediated pathology for NT1 has long been suspected given its exceptionally tight association with the MHC class II allele HLA-DQB1*06:02, as well as recent genetic evidence showing associations with polymorphisms of T cell receptor genes and other immune-relevant loci and the increased incidence of NT1 that has been observed after vaccination with the influenza vaccine Pandemrix. The search for both self-antigens and foreign antigens recognized by the pathogenic T cell response in NT1 is ongoing. Increased T cell reactivity against HCRT has been consistently reported in patients with NT1, but data demonstrating a primary role for T cells in neuronal destruction are currently lacking. Animal models are providing clues regarding the roles of autoreactive CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.